Jyh-Pyng Gau, MD

Education

College of Medicine, Taipei Medical University.

Faculty

Consultative physician, Taipei Veterans General Hospital

Experiences

Resident, Internal Medicine, Taipei Veterans General Hospital

Fellow, Division of Hematology, Taipei Veterans General Hospital                                                    

Attending physician, Division of Hematology & Oncology,, Department of Medicine, Taichung Veterans General Hosptial

Attending physician, Division of Hematology, Department of Internal Medicine, Taipei Veterans General Hosptial

Director, Comprehensive Hemophilia Treatment Center, Taipei Veterans General Hospital

Chief, Division of Hematology, Taipei Veterans General Hospital

License

Board of Internal Medicine

Board of Hematology

Board of Oncology

Board of Hematopoietic stem cell transplantation

Medical Expertise

Hematology, Anemia, Platelet and coagulation disorders, Hematological malignancies, High dose therapy and hematopoietic stem cell transplantation

Language

Mandarin, Taiwanese, English

Publications

1. Chen CC, Gau JP (co-first author), Chou HJ, You JY, Huang CE, Chen YY, Lung J, Chou YS, Leu YW, Lu CH, Lee KD, Tsai YH. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Ann Hematol. 2014;93:2029-2036.
2. Gau JP*(correspondence author), Chen CC, Chou YS, Liu CJ, Yu YB, Hsiao LT, Liu JH, Hsu HC, Chiou TJ, Chen PM, Tzeng CH. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation. Blood Cells Mol Dis. 2015;55(1):36-9
3. Chen CC, You JY, Lung J, Huang CE, Chen YY, Leu YW, Ho HY, Li CP, Lu CH, Lee KD, Hsu CC, Gau JP*(correspondence author). Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms. Haematologica. 2017 Mar;102(3):509-518.
4. C.F. Yang, J.P. Gau, L.T. Hsiao, C.Y Hsu. Clinical significance of blast percentage assessed by bone marrow trephine biopsy and aspirate smear of myeloid malignancies. Pathology 2021;53(6):740-745.